Gubra has a strong R&D pipeline for target discovery and peptide drug discovery. Our focus is on metabolic, fibrotic, and inflammatory diseases, where we are scientific experts.
Innovative and data-driven approach
Expert guidance in target and diseases
High quality data, integrity, speed and flexibility
Professional and agile project organization
Consult with Lise Biehl Rudkær
Director, Business Development
Choose the right, trustworthy discovery partner.
Healthy mix of internal & partnered programs
Gubra’s R&D Pipeline
Gubra´s R&D pipeline is a healthy mix of partnered programs and internal programs aimed for partnering now or at a later stage. Please get in contact if you would like to hear more.
Our scientific expertise and AI-driven platforms are key to our strong pipeline.
We combine our AI and machine-learning platforms with cutting-edge science to quickly move forward our programs. Our agile approach and complete in-house capabilities ensures speed and high data quality.
Niels Vrang, CSO (co-founder)
- Current collaboration partners: Boehringer Ingelheim, Bayer, and Silence Therapeutics
- A longterm trusted alliance partner
- Three projects in clinical development phase
- One project in Phase I
- A diverse portfolio of internal projects
- Ready to be partnered now or later
For further information
Hørsholm Kongevej 11B
+45 3152 2650